Efficacy and Safety of Tofacitinib versus Glucocorticoids in Patients with Active Segmental Vitiligo: A 72-Week, Single-Center, Parallel-Control, Open-Label, Randomized Extension Trial

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2025
This article has no abstract
Epistemonikos ID: 08c1db6bf54b92fcccbcb40b26ff9032e00a6553
First added on: Apr 24, 2026